Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated a notable improvement in financial performance, with a year-over-year operating margin increase of 180 basis points, driven by gross margin expansion and effective SG&A management, despite SG&A expenses rising to 39.5% of sales. The company reported a mid-single-digit revenue growth of 6.7% for 2024 and expects ongoing momentum in 2025, particularly with projected organic growth in its Cardiopulmonary segment of 7.0-8.0% due to successful product launches and market share gains. Additionally, LivaNova's capacity constraints for oxygenators are being addressed, with plans for a 10-15% capacity increase expected in 2025, which should further support revenue advancements as the demand from elective procedures rises post-pandemic.

Bears say

LivaNova's financial outlook is negatively impacted by a notable slowdown in organic revenue growth, which decreased to 7% in 4Q24 from 12% in the previous quarter, alongside a weak performance in the neuromodulation segment, which grew only 1.0% against consensus expectations. The company faces operational challenges, particularly in the international neuromodulation business, compounded by assumptions of continued headwinds in its Neuromodulation and Cardiovascular divisions, which may lead to overall revenue growth slowing to the low-single digits. Additionally, LivaNova's 2025 revenue guidance midpoint was slightly below consensus, indicating potential difficulties in meeting market expectations despite a comparatively favorable EPS guidance.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.